VHT vs XBI
Vanguard Health Care ETF vs SPDR S&P Biotech ETF
- • VHT has the lower expense ratio at 0.09% vs 0.35% for XBI.
- • VHT pays a higher dividend yield (1.58%).
Side-by-side metrics
| Metric | VHT | XBI |
|---|---|---|
Expense ratio Annual fee. Lower is better. | 0.09% | 0.35% |
Dividend yield Trailing 12-month yield. | 1.58% | 0.36% |
AUM Assets under management — bigger funds are typically more liquid. | $20.39B | $10.73B |
YTD return | 7.21% | 33.79% |
1-year return | — | — |
3-year return Annualized. | — | — |
5-year return Annualized. | — | — |
10-year return Annualized. | — | — |
Beta (3Y) Volatility relative to the market. Closer to 1 = market-like. | 0.57 | 1.10 |
P/E ratio | 26.46 | — |
Last price | $306.54 | $164.28 |
Inception | — | — |
Issuer | Vanguard | State Street |
VHT top holdings
| LLY | Eli Lilly and Co | 13.99% |
| JNJ | Johnson & Johnson | 8.44% |
| ABBV | AbbVie Inc | 6.07% |
| UNH | UnitedHealth Group Inc | 5.44% |
| MRK | Merck & Co Inc | 4.63% |
| TMO | Thermo Fisher Scientific Inc | 2.88% |
| AMGN | Amgen Inc | 2.86% |
| GILD | Gilead Sciences Inc | 2.63% |
| ISRG | Intuitive Surgical Inc | 2.38% |
| ABT | Abbott Laboratories | 2.35% |
XBI top holdings
| APGE | Apogee Therapeutics Inc | 1.49% |
| MRNA | Moderna Inc | 1.41% |
| TWST | Twist Bioscience Corp | 1.41% |
| ORKA | Oruka Therapeutics Inc | 1.38% |
| KYMR | Kymera Therapeutics Inc Ordinary Shares | 1.36% |
| VKTX | Viking Therapeutics Inc | 1.30% |
| PRAX | Praxis Precision Medicines Inc Ordinary Shares | 1.29% |
| ERAS | Erasca Inc | 1.27% |
| RVMD | Revolution Medicines Inc Ordinary Shares | 1.20% |
| RYTM | Rhythm Pharmaceuticals Inc | 1.20% |
About VHT
VHT (Vanguard Health Care ETF) is US health care sector stocks. Managed by Vanguard, the fund carries $20.4B in assets under management, an expense ratio of 0.09%, a dividend yield of 1.58%. Its largest holding is Eli Lilly and Co (LLY), which represents 14.0% of the portfolio. Technology is the fund's largest sector exposure at 0.0%.
About XBI
XBI (SPDR S&P Biotech ETF) is Equal-weight biotech stocks in the S&P Biotech Index. Managed by State Street, the fund carries $10.7B in assets under management, an expense ratio of 0.35%, a dividend yield of 0.36%. Its largest holding is Apogee Therapeutics Inc (APGE), which represents 1.5% of the portfolio. Financial Services is the fund's largest sector exposure at 0.5%.